Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery

Passeri, Thibault; Russo, Paolo di; Champagne, Pierre‐Olivier; Bernat, Anne-Laure; Cartailler, Jérôme; Guichard, J.-P.; Mammar, Hamid; Giammattei, Lorenzo; Adle‐Biassette, Homa; George, Bernard; Mandonnet, Emmanuel; Froelich, Sébastien

doi:10.1093/neuros/nyab164

Cited by 10 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the intraspinal seeding metastasis in the C1-C2 region, surgical resection was the first choice and the patient still required intensive follow-up. Recently, Passeri et al ( 7 ) suggested tumor growth rate (TGR), showing the percentage change in tumor size over 1 month, may be considered as a preoperative radiological indicator of tumor proliferation and seems to preoperatively identify more aggressive tumors with a higher tendency to recurrence.…”

Section: Discussionmentioning

confidence: 99%

Intradural spinal seeding metastasis of clival chordoma: a case report

Liu¹,

Li²,

Chen³

2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Clival chordoma is a locally aggressive tumor originating from remnants of the embryologic notochord. Although clival chordomas account for only 0.2% of all central nervous system tumors, they are characterized by local invasion and destruction, dural invasion, bone erosion, and cranial nerve palsy, and even metastasis.Case Description: We report a case of a 49-year-old female with an intradural spinal seeding metastasis 16 months after the initial endoscopic endonasal surgery (EES) for a clival chordoma. Gross total resection of tumor in upper clival region was achieved after initial EES and pathology revealed a classic chordoma.After 10 months, follow-up magnetic resonance (MR) showed a recurrence in situ and gamma knife was applied. After 16 months, the patient complained of neck pain and MR showed a new lesion in the spinal canal at C1 to C2 level. After craniotomy, the lesion in the spinal canal was totally removed, and pathology confirmed a chordoma with increased proliferative potential. The spinal chordoma might have occurred as a result of intradural spinal seeding metastasis through cerebral spinal fluid the during the initial operation.Conclusions: Chordomas are not only locally aggressive but also unpredictable and may metastasize through cerebral spinal fluid. Intensive follow-up is of great importance in the long term postoperatively time for clival chordoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Intradural spinal seeding metastasis of clival chordoma: a case report

Liu¹,

Li²,

Chen³

2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…It is widely accepted that whenever possible, total resection should be pursued ( 7 , 8 ). Chordoma in the sacrococcygeal region and other areas have a relatively high rate of total resection.…”

Section: Discussionmentioning

confidence: 99%

A correlation analysis of sacrococcygeal chordoma imaging and clinical characteristics with the prognostic factors

Zhao

Tian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo investigate the imaging and clinical risk factors related to the postoperative recurrence of sacrococcygeal chordoma.Methods63 patients of sacrococcygeal chordoma proved by operation and pathology in our hospital from January 2009 to December 2019 were retrospectively analyzed in the related factors of imaging manifestations, pathological type, and extent of surgical resection. The recurrence of sacrococcygeal chordoma was followed up. Univariate Kaplan-Meier survival analysis and multivariate Cox regression analysis were used to analyze the related factors of recurrence.ResultsOn plain radiographs and CT scans, chordoma primarily manifested as osteolytic bone loss and uneven soft tissue mass, with typical calcification or ossification (56.1 percent). Numerous chunk nodules with clearly high signal levels and short signal intervals were seen as the “pebble” in MRI characteristics on T2WI. The follow-up period ranged from 20 to 130 months, with a median time of 47.5 months. There were 14 recurrences (22. 2%) during the follow-up period. 13 patients with recurrence underwent surgery again, and 5 of them recurred after surgery (recurrence time range 3 to 97 months, median 38. 5 months). 6 (42.8%), 8 (57. 1%), and 13 (92. 9%) of the 14 patients with recurrence recurred within 2, 3, and 5 years after surgery, respectively. Univariate Kaplan-Meier survival analysis showed that occurred with local infiltration, Low differentiated chordoma, partial resection had a high postoperative recurrence rate, and all differences were statistically significant (P<0.05). Multi-factor Cox regression analysis showed whether local infiltration occurred and the degree of tumor resection were independent risk factors for tumor recurrence.ConclusionSacrococcygeal chordoma has a high tendency of recurrence, and the likelihood of recurrence is higher in tumor occurred with local infiltration, non-complete tumor resection and low differentiated chordoma, which can be considered to shorten the review cycle and complete tumor resection as much as possible during surgery.

show abstract

“…According to the methodology of a previous study, 17 Carestream R software (Carestream Health Inc) was used to semiautomatically quantify the volume of the tumor. In brief, the contours of the GCTB mass were manually traced at each imaging slice.…”

Section: Methodsmentioning

confidence: 99%

Tumor Growth Rate in Spinal Giant Cell Tumors of Bone and Association With the Immune Microenvironment and Denosumab Treatment Responsiveness: A Multicenter Study

Zheng

Niu

et al. 2022

Neurosurgery

View full text Add to dashboard Cite

BACKGROUND:Currently, little is known about the prognostic value of tumor growth rate (TGR) in spinal giant cell tumors of bone (GCTB).OBJECTIVE:To investigate the correlation of TGR with clinicopathological features, immune microenvironment, prognosis, and response to denosumab treatment of spinal GCTB.METHODS:A total of 128 patients with spinal GCTB treated at 5 centers from 2011 to 2021 were included. TGR was assessed by 2 independent neuroradiologists using at least 2 preoperative thin-section magnetic resonance imaging scans at a minimum interval of 2 months. Immunohistochemistry was used to assess tumor-infiltrating lymphocyte subtypes for CD3, CD4, CD8, CD20, PD-1, PD-L1, and Foxp3. Then, these parameters were analyzed for their associations with patient outcomes (progression-free survival and overall survival), clinicopathological features, and denosumab treatment responsiveness.RESULTS:High TGR predicted both poor progression-free survival and overall survival (both P < .001). In addition, TGR was associated with postoperative neurological dysfunction (P < .001), Enneking staging (P = .016), denosumab treatment responsiveness (P = .035), and the number of CD3+ (P < .001), PD-1+ (P = .009), PD-L1+ (P < .001), and FoxP3+ tumor-infiltrating lymphocyte (P = .02). Importantly, TGR outperformed the traditional Enneking, Campanacci, and American Joint Committee on Cancer staging systems in predicting the clinical outcomes of spinal GCTB.CONCLUSION:These data support the use of TGR as a reliable predictive tool for clinically relevant outcomes and response to denosumab therapy of spinal GCTB, which may be helpful in guiding prognostic risk stratification and therapeutic optimization of patients.

show abstract

Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery

Cited by 10 publications

References 43 publications

Intradural spinal seeding metastasis of clival chordoma: a case report

Intradural spinal seeding metastasis of clival chordoma: a case report

A correlation analysis of sacrococcygeal chordoma imaging and clinical characteristics with the prognostic factors

Tumor Growth Rate in Spinal Giant Cell Tumors of Bone and Association With the Immune Microenvironment and Denosumab Treatment Responsiveness: A Multicenter Study

Contact Info

Product

Resources

About